Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive tract. Even after surgical resection and standardized treatment, the recurrence rate and metastasis rate of this tumor remain high. Therefore, prognostic prediction of the clinical outcome of HCC patients is still a challenge for clinicians ([@b1-or-0-0-7238],[@b2-or-0-0-7238]). Although studies have suggested using different histological parameters to predict the prognosis of liver cancer cases, the new cancer classification system ([@b3-or-0-0-7238]) that uses molecular markers to interpret the prognosis of liver cancer patients has broad prospects.

lncRNAs play an important role in cancer research as they are involved in many aspects in the biological activity of tumors, such as transcription, epigenetic regulation, and mRNA expression, and are reported to play a suppressive role in breast as well as other cancers ([@b4-or-0-0-7238],[@b5-or-0-0-7238]). They may form pathways by interacting with miRNAs or mRNAs in human cancers. For example, lncRNA OIP5-AS1 was found to interact with miR-186a to inhibit ZEB1 expression in HCC which impaired tumor cell metastasis, and lncRNA HOXA-AS2 was found to suppress endothelium inflammation by regulating the activity of NF-κB signaling ([@b6-or-0-0-7238],[@b7-or-0-0-7238]). In the present study, lncRNA ZNF385D-AS2 was selected for research. lncRNA ZNF385D-AS2 may exert a regulatory function in various types of diseases and could regulate biological activities. Recently, lncRNA ZNF385D-AS2 has been suggested as a biomarker of novel stage in colorectal cancer progression although definite research is limited; however, whether ZNF385D-AS2 could also be a specific marker in liver cancer remains to be elucidated.

The aim of this study was to identify the pathological roles of ZNF385D-AS2 in liver cancer. In the present study, through a retrospective analysis of data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort and tissue chip data (GEO-GSE54236), we evaluated the potential prognostic significance of ZNF385D-AS2 in patients with liver cancer and assessed the independent prognostic value of ZNF385D-AS2 expression for overall survival of liver cancer patients. Then, Gene Set Enrichment Analysis (GSEA) was performed to gain further insight into the biological functions and proteins related to the ZNF385D-AS2 regulatory mechanism. Co-expression and ceRNA predictive analysis methods were performed to obtain 59 gene sets most closely related to ZNF385D-AS2. Finally, we also used tissue chip data (GEO-GSE54236) to analyze functional enrichment and enriched ZNF385D-AS2 targets for consistent upregulated and downregulated gene sets, using Circos plots to reveal them.

Materials and methods
=====================

### Data acquisition and collection

The data of liver cancer patients and RNA-seq expression results were downloaded with RTCGA Toolbox package in R (version 3.5.3) ([@b8-or-0-0-7238]). The gene microarray with cancer tissue data (GSE54236) ([@b9-or-0-0-7238],[@b10-or-0-0-7238]) was downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) ([@b11-or-0-0-7238]).

### Statistical analyses

SPSS software 23.0 (IBM Corporation, Armonk, NY, USA) was used for data analysis. Boxplots were used for discrete variables to measure the expression differences, and Chi-square tests were used to examine the correlation between ZNF385D-AS2 expression and clinical data ([@b12-or-0-0-7238]). Receiver-operating characteristic curve (ROC) was drawn by 'p-ROC package' to evaluate the capability of diagnosis. We divided patients into high and low ZNF385D-AS2 expression groups using the optimal cutoff value of overall survival (OS) as determined by the Youden index. Kaplan-Meier curves were used to compare the differences in the OS and relapse-free survival (RFS) by using survival package in R ([@b13-or-0-0-7238]). Univariate Cox analysis was used to select the related variables. Then, multivariate Cox analysis was applied for the influence of ZNF385D-AS2 expression on OS and RFS of the patients ([@b14-or-0-0-7238]).

### Gene set enrichment analysis (GSEA)

GSEA is a computational method that determines whether an *a priori* defined set of genes shows statistically significant concordant differences between two biological states. In this study, GSEA was performed by using GSEA software 3.0 from the Broad Institute (UC San Diego, San Diego, CA, USA) (<http://software.broadinstitute.org/gsea/index.jsp>) ([@b15-or-0-0-7238]). The gene expression data were RNA-seq data from TCGA-LIHC and GEO database. The gene set of 'c2. cp.biocarta.v6.2.symbols.gmt', 'c3. cp.biocarta.v6.2.symbols.gmt', 'c5.cp.biocarta.v6.2.symbols. gmt' and 'h.all.v6.2.symbols.gmt', which summarizes and represents specific, well-defined biological states or processes, was downloaded from the Molecular Signatures Database (<http://software.broadinstitute.org/gsea/msigdb/index.jsp>) ([@b15-or-0-0-7238]). The normalized enrichment score (NES) was acquired by analyzing with permutations for 1,000 times. A gene set was considered to be significantly enriched at a normal P-value \<0.05 and false discovery rate (FDR) \<0.25.

### Gene enrichment and functional annotation evaluation

The Database for Annotation, Visualization, and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>) and KO-Based Annotation System (KOBAS) (<http://kobas.cbi.pku.edu.cn/>) were used to conduct relevant pathway analysis ([@b16-or-0-0-7238],[@b17-or-0-0-7238]), and Gene Ontology (GO) analysis was performed for the functional annotation of the predicted genes ([@b17-or-0-0-7238]). Three GO terms \[biological process (BP), cellular component (CC) and molecular function (MF)\] were utilized to identify the enrichment of target genes. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed for the functional annotation of these genes. GO terms and KEGG pathway with P-values \<0.05 were considered statistically significant. The enrichment map of annotation analysis was drawn using Cytoscape (version 3.3.1) (<http://www.cytoscape.org/cy3.html>) and R (version 3.5.3).

### Co-expression genes and ceRNA pattern predictive analysis

In order to analyze the specific functions of lncRNA ZNF385D-AS2, it was necessary to analyze the interaction between lncRNAs and the coding genes as well as the interacting miRNAs ([@b18-or-0-0-7238]). Based on data from the TCGA-LIHC and GEO (GSE54236) databases, using the Pearson and Spearman correlation analysis based on the Logistic function ('WGCNA' package in R), the co-expression relationship between ZNF385D-AS2 and the coding genes and miRNAs were identified, and the co-expression network between ZNF385D-AS2 and the coding genes and miRNAs were mapped in Cytoscape. At the same time, comparative analysis of several lncRNA databases, such as NONCODE (<http://www.noncode.org/>), LncRBase (<http://starbase.sysu.edu.cn/>), Co-LncRNA (<http://www.biobigdata.com/Co-LncRNA/>), was carried out to identify the miRNAs that exhibited regulatory relationships with ZNF385D-AS2 and mRNAs which these miRNAs may regulate. After comparing the data from the TCGA and GEO databases, the possible ceRNA patterns in HCC were predicted and plotted which were also mapped in Cytoscape. Circos plots was generated based on the remappings from these two predicted results. Circos plots were generated using the Circos visualization tool in R ('RCircos' package in R) ([@b19-or-0-0-7238]).

Results
=======

### Patient characteristics

Both gene expression and clinical data of patients with liver cancer were downloaded from The Cancer Genome Atlas (TCGA-LIHC) database ([@b9-or-0-0-7238],[@b10-or-0-0-7238]). The total number of patients was 427. After initial screening, we omitted 13 normal samples and 74 tumor samples with missing or unclear information, and the remaining 303 tumor samples and 37 normal samples were available. The detailed clinical characteristics, including age, sex, TNM stage, survival status, pathological status, and ethnic compositions are shown in [Table I](#tI-or-0-0-7238){ref-type="table"}.

### Low expression of lncRNA ZNF385D-AS2 in HCC

Using boxplots, we measured the differences in ZNF385D-AS2 expression in liver cancer patients and control subjects. As shown in [Fig. 1A](#f1-or-0-0-7238){ref-type="fig"}, we evaluated the overall expression trend of ZNF385D-AS2 in liver cancer, then found that ZNF385D-AS2 expression was significantly lower in primary HCC tissues than that in normal liver tissues (P\<0.001). Moreover, as shown in [Fig. 1A-K](#f1-or-0-0-7238){ref-type="fig"}, there was differential ZNF385D-AS2 expression in the groups according to sex (P=0.046; [Fig 1C](#f1-or-0-0-7238){ref-type="fig"}), vital status (P=0.037; [Fig. 1D](#f1-or-0-0-7238){ref-type="fig"}), clinical stage (P=0.001; [Fig. 1E](#f1-or-0-0-7238){ref-type="fig"}), T stage (P=0.001; [Fig. 1F](#f1-or-0-0-7238){ref-type="fig"}) and survival time (P=0.033; [Fig. 1K](#f1-or-0-0-7238){ref-type="fig"}). Of note, differences in ZNF385D-AS2 expression were observed according to patient age as well as the TNM stage of cancer, and clinicopathological parameters ([Fig. 1](#f1-or-0-0-7238){ref-type="fig"}). We also collected data on the expression of ZNF385D-AS2 in several common digestive tumors based on TCGA database. After horizontal comparison, we found that except for cholangiocarcinoma and rectal cancer, the expression of ZNF385D-AS2 was reduced in most digestive system tumors ([Fig. 2](#f2-or-0-0-7238){ref-type="fig"}).

### Correlation between ZNF385D-AS2 expression and clinical features of the HCC samples

According to Chi-square tests, the correlation between the clinical features and the expression of ZNF385D-AS2 was analyzed and is documented in [Table II](#tII-or-0-0-7238){ref-type="table"}. The expression of ZNF385D-AS2 was highly associated with sex (χ^2^=3.846, P=0.050), T stage (χ^2^=3.875, P=0.049), M stage (χ^2^=4.221, P=0.040), N stage (Fisher\'s exact text, P\<0.001) and clinical stage (χ^2^=4.365, P=0.037).

### Low ZNF385D-AS2 expression is an independent prognostic factor for poor survival

We generated Kaplan-Meier curves of overall survival (OS), and log-rank tests showed that ZNF385D-AS2 low-expression was associated with poor OS (P=0.0079; [Fig. 3A](#f3-or-0-0-7238){ref-type="fig"}). Further subgroup analysis ([Fig. 3A-O](#f3-or-0-0-7238){ref-type="fig"}) showed that ZNF385D-AS2 low-expression was associated with the poor OS of patients with sex (male) (P=0.015; [Fig. 3D](#f3-or-0-0-7238){ref-type="fig"}), M0 stage (P=0.0099; [Fig. 3H](#f3-or-0-0-7238){ref-type="fig"}), N0 stage (P=0.028; [Fig. 3I](#f3-or-0-0-7238){ref-type="fig"}), age ≤55 (P=0.023; [Fig. 3J](#f3-or-0-0-7238){ref-type="fig"}), early pathological stage (G1/2) (P=0.044; [Fig. 3L](#f3-or-0-0-7238){ref-type="fig"}) and race (Asian) (P=0.0046; [Fig. 3N](#f3-or-0-0-7238){ref-type="fig"}).

As shown in [Fig. 4](#f4-or-0-0-7238){ref-type="fig"}, the ROC of ZNF385D-AS2 was executed, and the area under the curve (AUC) was 0.594, which represented moderate diagnostic ability.

In ZNF385D-AS2 low-expression patients, we used univariate analysis and selected the critical variables including age, sex clinical stage, pathological grade and TMN classification. Multivariate analysis with the Cox proportional hazards model indicated that clinical stage (HR=1.418, P=0.011) and T classification (HR=1.713, P\<0.001) were independent prognostic factors for patients with HCC ([Table III](#tIII-or-0-0-7238){ref-type="table"}).

### GSEA identifies the biological functions and proteins associated with ZNF385D-AS2

To identify the biological functions activated in liver cancer, we conducted GSEA between high and low ZNF385D-AS2 expression data sets. GSEA revealed significant differences (FDR \<0.25, P\<0.05) in the enrichment of 'MSigDB Collection', and the specific contents are shown in [Table IV](#tIV-or-0-0-7238){ref-type="table"}. In the nucleus, 'histone deubiquitination', 'V-D-J recombination' and 'translation factor activity RNA binding' were found to be differentially enriched in the ZNF385D-AS2 low-expression phenotype. Meanwhile, [Table IV](#tIV-or-0-0-7238){ref-type="table"} shows that 'cytoplasmic exosome RNase complex', 'nuclear exosome RNase complex', 'retrograde transport endosome to Golgi' and 'Golgi organization' exhibited a positive correlation with ZNF385D-AS2. In the cytoplasm, low expression of ZNF385D-AS2 was also related to various cytological behaviors such as 'protein transport along microtubule', 'negative regulation of defense response to virus' and 'oxidoreductase activity acting on the CNH group of donors NAD^+^ or NADP^+^ as acceptor'. Moreover, [Table IV](#tIV-or-0-0-7238){ref-type="table"} shows that as the expression of ZNF385D-AS2 is decreased, various intracellular signaling pathways are also affected. These signaling pathways encompass the metabolic synthesis and degradation of substances, such as 'one carbon pool by folate', 'glyoxylate and dicarboxylate metabolism', 'fatty acid metabolism', 'selenoamino acid metabolism', 'fructose and mannose metabolism' as well as 'aminoacyl tRNA biosynthesis', 'glycosyl-phosphatidylinositol GPI anchor biosynthesis', 'RNA degradation' and 'lysine degradation'. Moreover, it also affects signal transfer and material transport within HCC cells, including 'ABC transporters', 'Snare interactions in vesicular transport' and 'basal transcription factors', in addition to the progression of various diseases, including 'acute myeloid leukemia', 'hepatitis' and 'endometrial cancer'.

During the progression of liver cancer, the expression of ZNF385D-AS2 was found to gradually decrease. In this process, expression levels of a certain number of mRNAs were found to be altered as ZNF385D-AS2 decreased, and these results are summarized in [Table V](#tV-or-0-0-7238){ref-type="table"}. The expression levels of MEK, EGFR, ERB2, mTOR initially increased and then decreased. A positive regulation relationship was found between the expression levels of ZNF385D-AS2 and GLI1, CAMP, cyclin D1, Wnt. However, there still exists a negative regulatory relationship between the expression level of JAK2, PDGF-ERK and BRCA1. It is worth noting that P53, a gene that inhibits the development of cancer, was found to first decrease and then increase as the amount of ZNF385D-AS2 expression decreases.

### Prediction of related genes and functional annotation analyses

We next used R\'s 'edgr' package to calculate the difference (log fold-change \>1, P\<0.05) in expression between mRNAs, miRNAs and lncRNAs in the TCGA-LIHC and GEO (GSE54236) databases. Then we conducted comparative analysis of several lncRNA databases, such as NONCODE, LncRBase, Co-LncRNA to identify miRNAs that have regulatory relationships with ZNF385D-AS2 and mRNAs that these miRNAs may regulate. After comparing the data from the TCGA and GEO databases, the possible ceRNA patterns in HCC were predicted and plotted in Cytoscape ([Fig. 5A](#f5-or-0-0-7238){ref-type="fig"}). At the same time, we used Pearson and Spearman correlation analysis based on the Logistic function ('WGCNA' package in R), of the co-expression relationship between ZNF385D-AS2. The mRNAs and miRNAs were identified, and the co-expression network between ZNF385D-AS2 and the mRNAs and miRNAs was also mapped ([Fig. 5B](#f5-or-0-0-7238){ref-type="fig"}). The result strongly suggested that there is a regulatory signaling axis that exists between ZNF385D-AS2 and miR-96 and miR-182.

We then integrated the regulatory networks obtained by these two different methods, and again performed GO terms and KEGG pathway analyses for these mRNAs after removal of the duplicates. Cytoscape was used to conduct an analysis map of genes enriched in the GO terms and to construct an interaction network for the related genes ([Fig. 6A](#f6-or-0-0-7238){ref-type="fig"}). As shown in [Fig. 6B and C](#f6-or-0-0-7238){ref-type="fig"}, these specific mRNAs were most highly enriched in the following GO terms: Molecular function (MF) (growth factor activity, transforming growth factor β receptor binding), biological process (BP) (axon guidance, cell development, regulation of MAPK cascade, positive regulation of cell division, positive regulation of pathway-restricted SMAD protein phosphorylation, cell growth, SMAD protein signal transduction) and cellular component (CC) (extracellular space). Based on the results in [Fig. 5](#f5-or-0-0-7238){ref-type="fig"}, we used R to perform a dot-enrichment of the KEGG pathway obtained from KOBAS. These signaling pathways are able to affect material metabolism within HCC cells, signal transduction, progression of various diseases, and other biological behaviors ([Fig. 7](#f7-or-0-0-7238){ref-type="fig"}).

### Co-expression and ceRNA pattern regulated genome maps

Alignments of gene co-expression maps to GRCh38.95 identified reference genomic regions contributing to the composition of 59 genome sets. According to the co-expressing genes and ceRNA regulatory network predictive analysis results, we comprehensively analyzed the gene co-expression result and ceRNA regulatory network in GEO (GSE54236) and TCGA-LICH with ZNF385D-AS2. In order to find the most represented reference fragments, all GRCh38.95 loci present in the gene co-expressed maps were deduced and merged, resulting in 59 reference donor fragments, which settled in the outermost track. The numbers of gene co-expressed maps containing each of these fragment labels were then marked in the second track, excluding duplicate counts. We found 96 pairs of genes which existed in a co-expressed phenomenon. In the inner sector, we linked these pairs of gene sets that had co-expression relationships with lines. The sum of gene co-expressed map alignments across the whole genome was used as the links for the 59 gene co-expressed maps in the Circos plot ([Fig. 8](#f8-or-0-0-7238){ref-type="fig"}).

Discussion
==========

lncRNAs, as a group of genes, have been reported to be highly or lowly expressed in cancers. Furthermore, lncRNAs may serve as oncogenes, promoting the development of cancer by interacting with miRNAs and mRNAs to regulate cytological behavior ([@b20-or-0-0-7238]). As demonstrated by this research, lncRNA ZNF385D-AS2 plays an important role in HCC and can be used as a biomarker to monitor liver cancer prognosis. After analyzing the ZNF385D-AS2 expression in liver cancer patient samples, we found factors that are correlated with ZNF385D-AS2 low-expression, namely, sex, vital status, clinical stage, T stage and survival time.

Much research has been conducted in recent years concerning the role played by ZNF385D-AS2 in common digestive tumors where ZNF385D-AS2 was found to be downregulated ([@b21-or-0-0-7238]). Recently, it has been suggested that downregulation of ZNF385D-AS2 is involved in cancers including gastric cancer and human non-small cell lung cancer (NSCLC) although there is limited research to confirm this. Based on the present study, ZNF385D-AS2 low-expression was observed in liver cancer, consistent with the same ZNF385D-AS2 low-expression state concerning other types of tumors in the TCGA database. It is notable that ZNF385D-AS2 expression gradually decreased from T1 to T4 and from clinical stage I to clinical stage IV, suggesting its relevance in the progression of liver cancer. In addition, ZNF385D-AS2 expression was higher in male patients than female patients, suggesting its relevance to sex and the necessity to perform subgroup analysis. Especially in patients with a survival time of less than 3 years, this difference in expression was more pronounced. Moreover, low expression of ZNF385D-AS2 was associated with survival status, making it necessary to explore its link with survival. After analyzing the M and N stages of liver cancer, although the results did not achieve statistical significance, the expression level of ZNF385D-AS2 in M1 and N1 phase was lower than that in M0 and N0 phase.

Some previous studies also analyzed the way ZNF385D-AS2 affects the occurrence and development of tumors ([@b22-or-0-0-7238]). By large-scale clinical statistics, the obvious low-expression of ZNF385D-AS2 is found in many liver cell lines ([@b23-or-0-0-7238]). In this study, ZNF385D-AS2 can affect the initiation and proliferation of tumor, which explains that it is clinically related to the TNM classification. ZNF385D-AS2 exhibits a strong association with cancer prognosis. In the present study, it was found that low expression of ZNF385D-AS2 indicated a poor overall survival (OS), particularly in relation to age ≤55 years, sex (male), race (Asian), M0 stage, N0 stage as well as early histologic grade G1/G2. Cox analysis demonstrated the independent prognostic effect of ZNF385D-AS2 on the OS of patients; therefore, it can be used to monitor liver cancer as a biomarker. Some studies have also shown that in addition to affecting some of the common biological functions of tumor cells, lncRNA ZNF385D-AS2 can also affect some specific cytological behaviors although research is sparse confirming this. After functional enrichment analysis of ZNF385D-AS2, we found that ZNF385D-AS2 has a close relationship with the formation and efflux of exosomes. It is closely related to histone deubiquitination, V-D-J recombination and translation factor activity RNA binding, but also affects the regulation of defense response to virus, pre-autophagosomal membrane formation and as an acceptor acting on oxidoreductase activity. Not only that, but some of the intracellular signaling pathways are also affected. These signaling pathways encompass the metabolic synthesis and degradation of substances, such as 'one carbon pool by folate', 'glyoxylate and dicarboxylate metabolism', 'fatty acid metabolism', 'selenoamino acid metabolism', 'fructose and mannose metabolism' as well as 'aminoacyl tRNA biosynthesis', 'glycosyl-phosphatidylinositol GPI anchor biosynthesis', 'RNA degradation' and 'lysine degradation'. In the process, ZNF385D-AS2 also affects signal transfer, material transport within the cell and the progression of various diseases, including pathways for 'acute myeloid leukemia', 'hepatitis' and 'endometrial cancer'. Moreover, simultaneously with the gradual decrease in the expression of this special lncRNA, the expression of tumor-suppressor genes and oncogenes are also altered.

To further explore the biological role of ZNF385D-AS2 in HCC, we conducted a comparative analysis of the data from the TCGA and GEO databases and found approximately 59 genes that may be closely related to this special lncRNA. After functional enrichment of these genes with GO, we found that these genes play an important role in the following biological behaviors, such as molecular function (MF) (growth factor activity, transforming growth factor β receptor binding), biological process (BP) (axon guidance, cell development, regulation of MAPK cascade, positive regulation of cell division, positive regulation of pathway-restricted SMAD protein phosphorylation, cell growth, SMAD protein signal transduction) and cellular component (CC) (extracellular space). The result of the KEGG pathway analysis suggested that these genes can affect signaling pathways including material metabolism within HCC cells, signal transduction, progression of various diseases, and other biological behaviors. After integrating the data in TCGA and GEO, we obtained a total of 96 pairs of co-expressed gene pairs, including 59 genes of different types include mRNAs, miRNAs and lncRNAs. Finally, these data were integrated with gene expression and predicted for possible ceRNA regulatory network and the co-expression network. Finally, we performed whole-genome mapping by GRCh38.95, covering 96 co-expressed gene pairs representing the highest expression difference regions of the cancer genome. This allowed chained links to be directly observed without the need for complex algorithmic inferences reliant on intricate assumptions.

To the best of our knowledge, the present study, for the first time, confirmed that ZNF385D-AS2 greatly affects liver cancer prognosis. The present study, accompanied by other research on liver cancer, elucidated the importance of ZNF385D-AS2. Nevertheless, these findings should be verified in future studies with clinical trials, so as to ensure that ZNF385D-AS2 can be widely applied in the prognostic evaluation of liver cancer.

In conclusion, our study found that low expression of ZNF385D-AS2 was significantly decreased in HCC patients and is associated with several clinical features and a poor prognosis. Thus, ZNF385D-AS2 may be a useful biomarker for the prognosis of patients with liver cancer.
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###### 

Boxplots showing differences in ZNF385D-AS2 expression according to tissue type (A), patient age (≤55 vs. \>55 years) (B), sex (C) and survival status (D) as well as clinical stage (E), TNM stage (F-H), pathological status (I), race (J) and survival time (\>3 vs. ≤ years) (K). lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2.
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![lncRNA ZNF385D-AS2 expression in several common digestive system tumors based on TCGA database. The expression level of ZNF385D-AS2 in tumors was found to be lower than that in the normal tissues. The result data is logarithmically processed and its absolute value is calculated. lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2.](or-42-03-1110-g02){#f2-or-0-0-7238}

###### 

Kaplan-Meier curves for survival of HCC patients according to ZNF385D-AS2 expression in HCC tissues. Patients were divided into high and low ZNF385D-AS2 expression groups using the median value of ZNF385D-AS2 expression as the cut-off point. (A) Kaplan-Meier curves of overall survival (OS), and log-rank tests showed that ZNF385D-AS2 low-expression was associated with poor OS. Survival analysis and subgroup analysis according to clinical stage (B and C) and male sex (D) were performed based on Kaplan-Meier curves. HCC, hepatocellular carcinoma; lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2. Patients were divided into high and low ZNF385D-AS2 expression groups using the median value of ZNF385D-AS2 expression as the cut-off point. Survival analysis and subgroup analysis according to female sex (E) and TNM stage (F-H) were performed based on Kaplan-Meier curves. lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2. Patients were divided into high and low ZNF385D-AS2 expression groups using the median value of ZNF385D-AS2 expression as the cut-off point. Survival analysis and subgroup analysis according to TNM stage (continued) (I), age (J and K) and pathological status (L) were performed based on Kaplan-Meier curves. lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2. Patients were divided into high and low ZNF385D-AS2 expression groups using the median value of ZNF385D-AS2 expression as the cut-off point. Survival analysis and subgroup analysis according to pathological status (continued) (M), and race (N and O) were performed based on Kaplan-Meier curves. lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2.
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![ROC curve to identify the optimal cut-off value for dividing patients into high and low ZNF385D-AS2 expression groups. AUC, area under the curve; ROC, receiver-operating characteristic curve. HR, hazard ratio; lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2.](or-42-03-1110-g07){#f4-or-0-0-7238}

![Possible ceRNA regulatory and co-expression networks. (A) After comparing several lncRNA databases, the possible ceRNA patterns in HCC were predicted and plotted in Cytoscape. (B) Using the 'WGCNA' package in R, a possible co-expression regulatory network was mapped. The results highly suggest that there is a regulatory signaling axis between ZNF385D-AS2 and miR-96 and miR-182. ceRNA, competing endogenous RNA; HCC, hepatocellular carcinoma; lncRNA ZNF385D-AS2, long non-coding RNA zinc finger protein 385D antisense RNA 2.](or-42-03-1110-g08){#f5-or-0-0-7238}

![Significant GO terms identified by DAVID. (A) Cytoscape was used to conduct an analysis map of genes enriched in the GO terms and to construct an interaction network for the related genes. (B and C) mRNAs most highly enriched in the GO terms. GO, Gene Ontology. DAVID, Database for Annotation, Visualization and Integrated Discovery.](or-42-03-1110-g09){#f6-or-0-0-7238}

![Significant KEGG pathways identified by KOBAS. Using the genes predicted in [Fig. 5](#f5-or-0-0-7238){ref-type="fig"}, 29 different KEGG pathways were found to be enriched. These signaling pathways were roughly divided into four broad categories, of which 13 genes were most correlated. KOBAS, KO-Based Annotation System. KEGG, Kyoto Encyclopedia of Genes and Genomes.](or-42-03-1110-g10){#f7-or-0-0-7238}

![Circos plot derived from possible co-expression and ceRNA regulatory networks. Linked lines in the middle of the Circos plots show the relationship between each pair of co-expressed genes. The next track shows the labels of these genes. The outermost track shows the chromosome localization information of these genes. Plots were generated using the Circos visualization tool by R. ceRNA, competing endogenous RNA.](or-42-03-1110-g11){#f8-or-0-0-7238}

###### 

Demographic and clinical characteristics of the The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort (N=303).

  Characteristics          Number of samples, n (%)   
  ------------------------ -------------------------- ----------------
  Age (years)              n                          Percentage (%)
    ≤55                    107                        35.31
    \>55                   196                        64.69
  Sex                                                 
    Female                 92                         30.36
    Male                   211                        69.64
  T stage                                             
    T1                     153                        50.50
    T2                     76                         25.08
    T3                     63                         20.79
    T4                     10                         3.30
  Unknown                  1                          0.33
  M stage                                             
    M0                     229                        75.78
    M1                     3                          0.99
    Mx                     71                         23.43
  N stage                                             
    N0                     220                        72.61
    N1                     3                          0.99
    Nx                     80                         26.40
  Stage                                               
    I                      153                        50.50
    II                     74                         24.42
    III                    72                         23.76
    IV                     4                          1.32
  Histologic grade                                    
    G1                     42                         13.86
    G2                     144                        47.52
    G3                     105                        34.65
    G4                     12                         3.96
  Vital status                                        
    Living                 217                        71.62
    Deceased               86                         28.38
  Race                                                
    Asian                  150                        49.50
    Black                  8                          2.64
    Caucasian              139                        45.87
    Unknown                6                          1.98
  ZNF385D-AS2 expression                              
    Low                    184                        60.73
    High                   119                        39.27
  Total                    303                        100

###### 

Correlation of lncRNA ZNF385D-AS2 expression in HCC tissues and clinicopathologic variables of the HCC samples (N=303).

                                                                        ZNF385D-AS2 expression                     
  ------------- ------------------------------------------------- ----- ------------------------ ----- ----------- ----------------------------------------------------------
  Age (years)   ≤55                                               107   53                       54    0.006       0.938
                \>55                                              196   98                       98                
  Sex           Female                                            92    38                       54    **3.846**   **0.050**
                Male                                              211   113                      98                
  T stage       T1                                                153   84                       69    **3.875**   **0.049**
                T2                                                76    36                       40                
                T3                                                63    23                       40                
                T4                                                10    7                        3                 
  M stage       M0                                                229   107                      122   **4.221**   **0.040**
                M1                                                3     2                        1                 
                Mx^[a](#tfn2-or-0-0-7238){ref-type="table-fn"}^   71    42                       29                
  N stage       N0                                                220   106                      114               **\<0.001^[b](#tfn3-or-0-0-7238){ref-type="table-fn"}^**
                N1                                                3     0                        3                 
                Nx^[a](#tfn2-or-0-0-7238){ref-type="table-fn"}^   80    34                       46                
  Grade         G1                                                42    24                       18    2.038       0.564
                G2                                                144   69                       75                
                G3                                                105   47                       58                
                G4                                                12    5                        7                 
  Stage         Stage I/II                                        227   121                      106   **4.356**   **0.037**
                Stage III/IV                                      76    30                       46                
  Fustat        Surviving                                         217   102                      115   3.055       0.081
                Deceased                                          86    50                       36                
  Race          Asian                                             150   77                       73    0.004       0.950
                Other race                                        147   76                       71                

Bold P-values indicate statistically significant correlations (P≤0.05).

Not included in the analysis.

Fisher\'s exact text. HCC, hepatocellular carcinoma.

###### 

Univariate and multivariate analyses of OS in patients with liver cancer with low expression of lncRNA ZNF385D-AS2.

                                          Univariate analysis   Multivariate analysis                                        
  --------------------------------------- --------------------- ----------------------- ------------- ------- -------------- -------------
  Age, years (≤55 vs. \>55)               1.361                 0.991--1.041              0.243                              
  Sex (female vs. male)                   0.691                 0.419--1.476              0.681                              
  Race (Asian vs. Black and Caucasian)    0.988                 0.449--0.991            0.32                                 
  Grade (G1 and G2 vs. G3 and G4)         0.044                 0.722--1.612              0.835                              
  Stage (Stage I and II vs. III and IV)   1.813                 1.257--2.405              **0.013**   1.418   0.926--2.452     **0.011**
  T stage (T1 and T2 vs. T3 and T4)       2.299                 1.594--3.401            **\<0.001**   1.713   1.269--3.120   **\<0.001**
  M stage (M0 vs. M1)                     2.282                 1.994--2.407              0.059                              
  N stage (N0 vs. N1)                     1.119                 1.063--1.376              0.073                              

Bold P-values indicate statistical significance (P\<0.05). OS, overall survival; HR, hazard ratio; CI, confidence interval.

###### 

lncRNA ZNF385D-AS2 low-expression related GO terms and KEGG pathways in HCC.

  GO Terms                                                       Size       ES          NES         NOM P-value
  -------------------------------------------------------------- ---------- ----------- ----------- -----------------
  GO_DEOXYRIBONUCLEOSIDE_TRIPHOSPHATE_METABOLIC_PROCESS          16         0.6713025   1.8666009   \<0.001
  GO_HISTONE_MRNA_METABOLIC_PROCESS                              28         0.5867406   1.8163215   0.010204081
  GO_TRANSLATION_FACTOR_ACTIVITY_RNA_BINDING                     83         0.3732794   1.7212093   0.030425964
  GO_SOMATIC_CELL_DNA_RECOMBINATION                              33         0.6081087   1.7152647   0.0078125
  GO_V\_D_J\_RECOMBINATION                                       16         0.7184384   1.7132919   \<0.001
  GO_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH                    18         0.6175537   1.7093326   0.010162601
  \_NH_GROUP_OF_DONORS_NAD_OR_NADP_AS_ACCEPTOR                   21         0.5698847   1.6803491   0.024340771
  GO_EXOSOME_RNASE_COMPLEX\_                                     19         0.5726633   1.6542872   0.017928287
  GO_TELOMERASE_HOLOENZYME_COMPLEX                               18         0.5810587   1.6540635   0.035781544
  GO_MICROTUBULE_NUCLEATION                                      41         0.5348539   1.6465995   0.033663366
  GO_SOMATIC_DIVERSIFICATION_OF_IMMUNE_RECEPTORS                 20         0.6116292   1.6374387   0.019880716
  GO_NUCLEAR_LOCALIZATION_SEQUENCE_BINDING                       18         0.4993185   1.6094043   0.042307694
  GO_NEGATIVE_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS            15         0.5706286   1.6084776   0.03206413
  GO_CYTOPLASMIC_EXOSOME_RNASE_COMPLEX\_                         22         0.5604809   1.5993211   0.05668016
  GO_SNRNA_PROCESSING                                            71         0.3641102   1.5988086   0.05078125
  GO_RETROGRADE_TRANSPORT_ENDOSOME_TO_GOLGI                      27         0.5950033   1.5972574   0.038910504
  GO_PROTEIN_TRANSPORT_ALONG_MICROTUBULE                         16         0.5016319   1.5902865   0.060546875
  GO_PRE_AUTOPHAGOSOMAL_STRUCTURE_MEMBRANE                       84         0.3968728   1.5886257   0.05668016
  GO_GOLGI_ORGANIZATION                                          15         0.5812139   1.5849311   0.037254903
  GO_NUCLEAR_EXOSOME_RNASE_COMPLEX_GO_HISTONE_DEUBIQUITINATION   21         0.5922844   1.5812734   0.035785288
                                                                                                    
  **KEGG Pathways**                                              **Size**   **ES**      **NES**     **NOM P-value**
                                                                                                    
  KEGG_ONE_CARBON_POOL_BY_FOLATE                                 17         0.5607268   1.6354854   0.02028398
  KEGG_RNA_DEGRADATION                                           57         0.383115    1.6217419   0.04722793
  KEGG_GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM                   16         0.5347747   1.4103469   0.10763209
  KEGG_ABC_TRANSPORTERS                                          44         0.4471579   1.2647074   0.16201118
  KEGG_LYSINE_DEGRADATION                                        44         0.417074    1.318973    0.21428572
  KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT                 37         0.3300203   1.2587498   0.21875
  KEGG_AMINOACYL_TRNA_BIOSYNTHESIS                               41         0.3709021   1.1858624   0.3238289
  KEGG_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR_BIOSYNTHESIS      25         0.3702377   1.155113    0.33463797
  KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_KERATAN_SULFATE            15         0.4000842   1.1251451   0.33675563
  KEGG_BASAL_TRANSCRIPTION_FACTORS                               32         0.3257739   1.1036584   0.35135135
  KEGG_PROXIMAL_TUBULE_BICARBONATE_RECLAMATION                   23         0.4029235   1.0807126   0.35238096
  KEGG_MISMATCH_REPAIR                                           23         0.4058034   1.1521276   0.35966736
  KEGG_NUCLEOTIDE_EXCISION_REPAIR                                43         0.3010005   1.1056284   0.3783231
  KEGG_SPLICEOSOME                                               125        0.2617425   1.0658554   0.39430895
  KEGG_ACUTE_MYELOID_LEUKEMIA                                    57         0.2873536   1.0399672   0.3966597
  KEGG_FATTY_ACID_METABOLISM                                     41         0.4589222   1.121886    0.41860464
  KEGG_SELENOAMINO_ACID_METABOLISM                               26         0.2914508   1.023621    0.42376238
  KEGG_PEROXISOME                                                78         0.3360126   1.045031    0.4318182
  KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM                           34         0.2906978   0.9975369   0.45
  KEGG_ENDOMETRIAL_CANCER                                        52         0.2653771   0.9771847   0.45436105

Enrichment Biological Functions from GSEA. HCC, hepatocellular cancer; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, Gene Set Enrichment Analysis; ES, Enrichment Score; NES, Normalized Enrichment Score.

###### 

Enrichment of gene expression from GSEA.

  Expression change                Gene name
  -------------------------------- --------------------------------------------------------------------------------
  Decreased expression             *JAK2, SIRNA, PDGF, BCAT, STK33, RB, TBK1, EIF4E, BRCA1*
  Increased expression             *CSR, STK33, STK33, GLI1, CAMP, PIGF, EGFR, STK33, KRAS, TBK1, Cyclin D1, Wnt*
  First increased then decreased   *VEGF, CSR, ESC, CRX, MTOR, MEK, EGFR, ERB2, LTE2, LEF1, GLI1, RAF, ATF2*
  First decreased then increased   *HOXA9, RB, P53*

Notably, upon lncRNA ZNF385D-AS2 low-expression, the expression levels of other genes were found to be altered. GSEA, Gene Set Enrichment Analysis.
